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Abstract 
Myasthenia gravis (MG) is an autoimmune disease affecting the neuromuscular transmission 
(NMT) due to autoantibodies raised against muscle-type nicotinic acetylcholine receptors 
(nAChR) (Lang et al. 2003). Therapeutic strategies to control muscle weakness and fatigability 
are mainly devoted to counteract excessive immune responses, with corticosteroids as first line 
resource. Recently, it was demonstrated that methylprednisolone (MP) increases adenosine 5’-
triphosphate (ATP) release above baseline from resting motor endplates, which anticipates 
adenosine (ADO) accumulation at the synaptic cleft thus contributing to amplify NMT via the 
activation of presynaptic facilitatory adenosine A2A receptors (A2AR) (Oliveira et al. 2015a). 
Since endogenous ADO generated during nerve stimulation in myasthenic motor endplates, is 
insufficient to sustain transmitter release demand through tonic activation of A2AR (Oliveira et al. 
2015b), we hypothesized that benefits of corticotherapy (recovery from neuromuscular failure) 
in myasthenics, may result from the rehabilitation of the ADO A2AR tonus, leading to increases 
the acetylcholine (ACh) release and muscular strengthening. 
In this study, we used Wistar rats with experimental autoimmune myasthenia gravis (EAMG), 
which were immunized with the R97-116 peptide, a synthetic peptide corresponding to a 
specific region on the α subunit of the rat nicotinic AChR, made up in a solution containing the 
Complete Freund’s Adjuvant (CFA) (Oliveira et al. 2015b). Thirty days after the first inoculation, 
the animals were boosted with the R97-116 peptide made up with the Inactive Freund’s 
Adjuvant (IFA). Control animals received the CFA emulsion without the peptide. Animals from 
the Naïve group were not submitted to treatment. Clinical scoring was based on the presence of 
tremor, hunched posture and fatigue. Muscle strength was assessed by the grip strength test 
(BIOSEB, France). 
Pre-treatment of hemidiaphragm preparations isolated from EAMG rats with methylprednisolone 
300 µM (MP 300 µM) significantly increased acetylcholine ([3H]-ACh) release evoked by phrenic 
nerve stimulation with 50 Hz Bursts. No significant changes (p˃0.05) were detected, when 
comparing the facilitatory effect of MP (300 µM) in EAMG (33±14%, n=5) with Control (24±3%, 
n=6) and Naïve (40±11% n=5). Despite the reported loss of A2AR tonus in EAMG rats (Oliveira 
et al. 2015b) amplification of NMT induced by MP (300 µM) is dependent of A2AR activation, 
because the facilitatory effect of MP (300 µM) was prevented by the A2AR antagonist, 4-(2-(7-
amino-2-(furan-2-yl)-[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-ylamino)ethyl)phenol (ZM 241385) (50 
nM). Like in both Naïve and Control animals, MP (300 µM) also significantly (p<0.05) increased 
the outflow of ATP in resting motor endplates of EAMG rats from a basal level of 526±71 pM to 
794±71 pM (n=5) using the luciferin-luciferase bioluminescence assay. 
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Data show here, for the first time, that MP can rehabilitate NMT failure in EAMG animals, by 
increasing the outflow of ATP from resting motor endplates, which upon its extracellular 
hydrolysis into ADO may enhance the A2AR tonus leading to facilitation of evoked transmitter 
release during high-frequency nerve firing. 
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mA - Milliamps  
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SEM - Mean standard error 
sc - Subcutaneous 
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2. Introduction 
2.1. Myasthenia Gravis – “Myasthenia” Greek (muscle weakness) and “gravis” Latin 
(severe) 
Acquired Myasthenia Gravis (MG) is a relatively rare autoimmune neuromuscular disorder, 
clinically characterized by muscle weakness and fatigability, as a result of the production of 
autoantibodies against proteins of the postsynaptic membrane in the neuromuscular junction 
(NMJ). About 85% of patients with MG have immunoglobulin G (IgG) autoantibodies against 
binding sites on the nicotinic acetylcholine receptor (nAChR) (Lindstrom et al. 1976; Shigemoto 
et al. 2006; Cavalcante et al. 2011; Aviden et al. 2014). Other patients have autoantibodies 
against muscle-specific kinase (MuSK) (8%) and low-density lipoprotein receptor-related protein 
4 (LRP4) (5%) (Berrih-Aknin et al. 2014; Huijbers et al. 2014). It is also described a distinct 
myasthenic syndrome, Lambert-Eaton myasthenic syndrome (LEMS) (2%), an autoimmune 
disorder characterized by antibodies (Abs) raised against the presynaptic Cav2.1 voltage-gated 
calcium channels (VGCC) (Huijbers et al. 2014; Ha & Richman 2014). 
There are multiple mechanisms that explain how nAChR autoantibodies interfere with the 
normal function of the NMJ: (1) complement-mediated inflammatory destruction of the post-
synaptic membrane of skeletal muscle cells (Tüzün et al. 2003); (2) antigenic modulation by 
cross-linking of the target antigen; competition at ligand-binding sites; (3) steric hindrance that 
inhibits conformational changes interactions with associated molecules, reducing the nAChR 
number on muscle fibers and consequently decreasing neuromuscular transmission (NMT) (Ha 
& Richman 2014). The relative contribution of these mechanisms to the pathophysiology of all 
forms of MG depends on the epitope specificity of the autoantibody and the immunoglobulin 
subclass involved (Huijbers et al. 2014). The T lymphocytes lead the attack to motor endplates, 
by recognition of the antigen coupled to the major histocompatibility complex class II (MHC II), 
thus promoting B lymphocytes production of anti-AChR (primarily isotypes IgG1 e IgG3) Abs. 
(Rodgaard et al. 1987; Aviden et al. 2014; Huijbers et al. 2014; Ha & Richman 2014).  
Epidemiological analysis of human patients with MG exhibiting autoantibodies against AChR 
revealed a bimodal distribution: early onset MG – with female predominance at 20-40 years of 
age (Carr et al. 2010); and late onset MG – with male predominance at 60-80 years of age, and 
in this group there is a higher rate of association with thymoma (Muller-Hermelink & Marx 2000; 
Huijbers et al. 2014). Between the ages of 50-60 there is no gender difference in predominance 
of MG (Carr et al. 2010; Berrih-Aknin et al. 2014). The disease usually begins with ocular 
symptoms and extends to other muscles in 80% of cases. It also includes other features: 
variability, effort induced worsening, successive periods of exacerbation during the course of 
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the disease, severity dependent on respiratory and swallowing impairment (myasthenia crisis if 
acute evaluation). The diagnosis is based on the clinical features, the benefit of the 
cholinesterase inhibitors (hydrophonium or edrophonium intravenous (iv) has a brief response in 
3-5 minutes (min); neostigmine subcutaneous (sc)/intramuscular (im) from 15 min to 2 hours (h) 
reverts ptosis, hypernasal voice, limb weakness), the detection of autoantibodies and significant 
decrement evidenced by electrophysiological tests (Berrih-Aknin et al. 2014). 
Reestablishment of NMT is the main goal for the current MG therapeutics and could be 
achieved by two different approaches. Symptomatic therapy is often needed, which includes 
cholinesterase inhibitors that partially compensate for the reduced safety margin of NMT acting 
postsynaptically. However, the increasing ACh bio-availability induced by acetylcholinesterase 
(AChE) inhibitors has some undesirable systemic side effects, like autonomic and (cholinergic 
crisis very similar to MG crisis). Another strategy of treatment is based on early intervention with 
immune suppression to limit epitope spread and long-term disease severity, like 
plasmapheresis, thymectomy, iv administration of immunoglobulins and immunosuppressive 
drugs, such as corticosteroids and azathioprine, to inhibit humoral and cellular immune 
responses in order to reduce skeletal muscle destruction (Berrih-Aknin et al. 2014; Huijbers et 
al. 2014). 
Safer and specific therapies in myasthenic syndromes are still required, because of the potential 
for serious side effects associated with present broad immunosuppressive and 
anticholinesterase therapies. 
2.2. Myasthenia Gravis therapeutic approach in Veterinary Medicine 
Many of the newest therapeutic options available in veterinary medicine for MG, are based on 
current strategies used in Humans with this disease (Khorzad et al. 2011). MG is likely the most 
commonly diagnosed neuromuscular disease in small animal practice, and is relatively common 
in dogs. While diagnosing and treating dogs and cats with MG is rewarding, it can be 
devastating if not recognized early and treated appropriately. Ormrod described MG in a dog in 
1961 and Dawson in a cat in 1970. The autoimmune form of canine MG was described in 1978 
by Lennon and collaborators (reviewed in Vernau 2009). Acquired MG is the most commonly 
recognized immune-mediated neurological disease affecting dogs and occasionally cats 
(Shelton 2002; Platt & Olby 2004). “Acquired MG has been observed in dogs older than 3 
months, of all breeds but particularly in German Shepherd Dogs, Golden Retrievers and 
Labrador Retrievers. In one report, the relative risk of acquired MG in different breeds of dogs 
was highest in Akitas (Shelton et al. 1997; Andrade et al. 2007). Newfoundlands may also be 
predisposed to acquired MG” (Platt & Olby 2004), as well as Great Danes (Dewey et al. 1988-
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1995; Lorenz et al. 2011), German Shorthaired Pointer and Chihuahua (Shell 2012). Machado 
& Brizzotti (2012) reported a case of acquired MG in a poodle. A bimodal age of onset, like in 
Humans has also been reported in affected dogs (˂5 - >7 years) (Platt & Olby 2004; Shell 
2012). In one review of cats with acquired MG, gender was not a risk factor (Shelton et al. 2000; 
Platt & Olby 2004). There is a higher incidence in Abyssinians, Somalis and domestic shorthair 
cats (Lorenz et al. 2011; Machado & Brizzotti 2012).  
Acquired MG is classified based on distribution and severity of clinical signs, and can be 
classified into 4 major groups, those with only focal clinical signs without generalized weakness, 
mild cases with a progressive generalized weakness in the absence of megaesophagus, those 
with a more severe form - fulminant - acute generalized weakness and megaesophagus, or as a 
paraneoplastic syndrome associated with thymoma (Abelson et al. 2009; Khorzad et al. 2011).  
In focal MG, there is no clinical evidence of thoracic or pelvic limb muscle weakness; instead 
weakness occurs in 1 or more muscle groups including the facial, esophageal, pharyngeal and 
laryngeal muscles. A dog may present only megaesophagus, being the regurgitation or 
dysphagia the only clinical signals (36 – 43 % of all canine cases) (Khorzad et al. 2011), while in 
cats megaesophagus and dysphagia occurs in approximately 15% of cases (Platt & Olby 2004). 
This is explained by the composition of the muscularis externa in the esophagus. In the dog the 
muscular externa is mainly composed by skeletal muscle, while in the cat, the muscularis 
externa is composed by skeletal muscle throughout much of the esophagus, but in the caudal 
one-fifth there is a transition to smooth muscle (Bacha & Bacha 2000). In Humans, where only 
the proximal 2 – 6 centimeters of the muscularis externa of the esophagus is skeletal muscle, 
with the remainder being smooth muscle, megaesophagus is not common (Abelson et al. 2009). 
Fifteen percent of people have focal MG restricted to the eyes (Khorzad et al. 2011). 
Generalized MG can manifest in a wide range of clinical signals, ranging from mild to severe 
weakness to megaesophagus. In animals, the pelvic limbs are more affected than the thoracic 
limbs. Generalized MG occurs in 57 – 64 % of all canine cases, with 90% of them having 
megaesophagus (Khorzad et al. 2011), while generalized weakness without megaesophagus 
occurs in approximately 30% of cats and generalized weakness and megaesophagus/ 
dysphagia occurs in 20% of cats (clinical signals in this species is more variable) (Platt & Olby 
2004; Lorenz et al. 2011). An acute fulminant form of MG with a rapid onset of paralysis and 
megaesophagus, frequent episodes of regurgitation with secondary aspiratory pneumonia, and 
respiratory distress, occurs in less than 5% of dogs, compared to the 12% of cases in Humans, 
identified in a study conducted in China by Yu and collaborators (Yu et al. 1992; Khorzad et al. 
2011). MG may be developed as a part of a paraneoplastic syndrome, and affected animals 
may display clinical signs related to a primary neoplasm (thymomas, osteogenic sarcoma, 
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cholangiocellular carcinoma, anal sac adenocarcinoma and lymphoma). MG has been identified 
in 30 – 50 % of dogs with thymomas but the incidence of thymoma associated with MG is higher 
in cats than in dogs (Lorenz et al. 2011; Khorzad et al. 2011). It is referred that the incidence of 
mediastinal thymoma occurs in 25.7% of cats with MG, and in dogs the incidence is 3.4% (Platt 
& Olby 2004). In Humans 30 – 60% of thymomas are associated with MG according to Vincent 
and collaborators (Vincent et al. 2001; Khorzad et al. 2011). 
The diagnosis of MG begins with the correct evaluation of the patient, proper anamnesis, 
physical examination, including neurological examination, which should lead to suspect from 
MG. Clinical signs usually consist of all or some of the following: exercise-induced weakness 
(after rest they walk normally for a short period before the stride shortens, until they crouch in 
sternal recumbency and rest their head on their forepaws), fatigue, pelvic limb weakness or 
stiffness, megaesophagus, reduced gag response, voice change, neck weakness, and facial 
weakness (Shell 2012). Many cats have facial weakness, with dropped jaw, are unable to close 
their eyes and manifest ventro-flexion of the neck (Platt & Olby 2004; Lorenz et al. 2011). A 
presumptive diagnosis of MG may be made by the resolution of muscle weakness following an 
iv injection of edrophonium chloride. Thorax radiography is indicated to detected secondary 
aspiration pneumonia, cranial mediastinal mass, megaesophagus and pneumonia or 
pneumonitis (Shell 2012). Currently, serum Abs against nAChR (MG titer) is the “gold standard” 
test for diagnosing acquired MG by immunoprecipitaion radioimmunoassay (RIA); this test is 
specific, sensitive and an nAChR Abs titer ˃0.6 nanomol per liter (nmol/L) is diagnostic in dogs 
(Khorzad et al. 2011) and ˃0.3 nmol/L is positive in cats (Shelton 2010). To date, Abs against 
muscle-specific kinase (MuSK) have been identified in only one MG canine, which was 
seronegative to nAChR Abs (Shelton 2010). Similar to Humans, Shelton and collaborators in 
2001 described cases of canine MG with autoantibodies against skeletal muscle striations in 
dogs with thymomas, against titin in older-onset MG and against ryanodine receptor in severe 
forms of thymoma-associated MG (Shelton 2010). Repetitive nerve stimulation, performed 
under general anesthesia (which can present serious risks for the patient), can be used to 
support the diagnosis of MG, especially in cases that have negative nAChR Abs test results. 
Findings that support the diagnosis of MG are: reduced amplitude of compound muscle action 
potentials (CMAPs), decrease of the CMAPs with repetitive stimulation (and its reversal with an 
iv administration of edrophonium) (Shell 2012). 
Shelton and Lindstrom, in 2001, confirmed that in the absence of immunosuppression, the 
natural course of canine MG is for clinical and immune remission (clinical signs resolved and 
Abs titters within the reference interval) and therefore immunosuppressive drugs should not be 
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used unless in severe cases of MG, which do not respond to AChE treatment alone (Shelton 
2010).  
In acquired MG, there are three major modalities of therapeutic intervention: anticholinesterase 
therapy, immunomodulatory therapy, and thymectomy. In Veterinary Medicine, 
anticholinesterase therapy is most widely accepted. Long-acting anticholinesterase drugs 
prolong the action of ACh at the NMJ by reversibly inhibiting AChE. The agent most often used 
is pyridostigmine bromide (Mestinon®, 0.5 to 3 milligram per kilogram (mg/Kg) every 8 h (QID) 
to 12 h (BID) per os (po)). To avoid overstimulation of AChR, treatment is started at the low end 
of the dosage range, and the dose is gradually increased to effective dosages (Lorenz et al. 
2011). Patients that cannot tolerate the oral form, because of frequent regurgitation from 
megaesophagus are treated with neostigmine bromide, which is administered at 0.04 mg/kg 
four times a day (QID) im (Abelson et al. 2009). The dosages are titrated to an optimal level 
based on changes in muscle strength. Some dogs with megaesophagus may simply require 
elevated feedings, while some may require placement of a gastrotomy tube (in case of 
intractable regurgitation, even with altered feeding techniques). Generally dogs and cats should 
be feed two to three times daily, in an elevated (standing or upright sitting) position for 20-30 
min, after each feeding. Joe and Donna Koch developed the "Bailey Chair”, where the dogs are 
comfortable, can eat, drink, receive medications, and remain in a stable, upright position 
following a meal. The consistency of the food (liquid, solid, gruel) may also need to be altered 
depending on which is handled best (Shell 2012). Cats are sensitive to anticholinesterase 
drugs, and do not appear to suffer from the muscular weakness secondary to corticosteroids 
that dogs do, particularly when high dosages are used. Therefore, the first line treatment for 
cats with MG is immunosuppression with corticosteroids. In dogs and cats with thymoma, 
complete excision results in clinical and immunological remission of MG (Vernau 2009). While 
there are not any controlled trials to address the optimum treatment for cats and dogs with 
thymomas or those that respond poorly to medications, surgical excision is currently believed to 
be the ideal treatment (Lorenz et al. 2011). It should be taken alternative treatments in case of 
secondary aspiratory pneumonia, severe generalized MG and fulminant MG (ventilatory support 
may be needed). The key to a successful outcome may be the prevention and/or aggressive 
treatment of aspiration pneumonia, since the mortality rate in acquired MG approaches 
approximately 50%, due in large part to misdiagnosis of vomiting instead of regurgitation from 
esophageal weakness and dilatation. In the absence of severe aspiration pneumonia, 
pharyngeal weakness, or acute fulminating MG, the prognosis for survival and complete 
remission is usually good (Shell 2012). 
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There are documented two case reports of acquired MG in other species, in a 14 years old 
female polar bear (Ursus maritimus) which acutely developed hind limb weakness (Kenny et al. 
2004) and in a 7 months-old male ferret (Mustela putorius furo), evaluated for episodic pelvic 
limb weakness of 2 weeks´ duration (Couturier et al. 2009). These cases have clinical relevance 
because in the future, veterinarians with a case of a muscle weakness in these species should 
consider MG as a differential diagnosis, and even though the gold standard diagnosis method is 
relatively species-specific, it may occur some cross-reactivity in Abs recognition of the nAChRs 
between species, as referred in these reports. 
2.2.1. Animal models to study Myasthenia gravis 
Laboratory animal science is defined as the study of the scientific, ethical and legal use of 
animals in biomedical research. It comprehends a multidisciplinary field encompassing 
biological and pathobiological specialties for the optimal use of animals as models, either for 
humans, or other species. Cause, nature and cure of diseases are the main purposes for the 
use of these models, and in the study of MG are developed and used induced experimental 
disease models. It is important to have in mind the similarities and the differences of the species 
chosen, and the resemblance pathology and outcome of an induced disease or disorder in the 
model species, with the respective lesions of the target species, so the experimental results can 
be extrapolated from one species to the other (Hau & Van Hoosier Jr 2003). If there is an 
experimental model already accepted and validated for the disease to be tested (the etiology, 
course and pathology similarities/differences between the induced model, and humans for 
example, are known) it should be preferred. Few induced models completely mimic the target 
disease in Human´s (Hau & Van Hoosier Jr 2003). 
Patrick and Lindstrom in 1973 immunized rabbits in order to obtain autoantibodies against the 
recently purified nAChR, and observed that the animals developed weakness and 
electrophysiological abnormalities that were similar to those in human MG (Patrick & Lindstrom 
1973). This experimental disorder in rabbits, received lately the name Experimental 
Autoimmune Myasthenia Gravis (EAMG). Later EAMG was reproduced in other species 
(Lennon et al. 1975) and has contributed with a great deal of information for unveiling the 
molecular and immunological features of this disease. There are numerous procedures to 
create an animal model for MG. A very common one, which recreates most of the observed 
symptoms of MG in Humans (Attachment 1), consists on injecting rodents with anti-nAChR Abs 
and/or their immunization with nAChRs isolated from Torpedo californica (Aricha et al. 2006). 
Baggie and collaborators showed that the breaking of tolerance to a single T cell epitope of the 
self-autoantigen induces autoreactive T cells and specific Abs to rat AChR (Baggi et al. 2004). 
This model was established by immunizing a susceptible rat strains (Lewis rats) with a synthetic 
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peptide corresponding to region α97-116 of the rat AChR α subunit, in CFA (Complete Freund’s 
Adjuvant – a mixture of oils and water plus killed Mycobacterium tuberculosis strain, used to 
stimulate immune response). This model of EAMG is valid as a model to understand the key 
immunological processes and molecular aspects, leading to MG as well as providing a practical 
instrument for testing the capability of possible treatment methods for MG and other antibody-
mediated autoimmune diseases (Baggi et al. 2012).  
It is also possible to induce nonimmunogenic MG in animals by administration of AChR-blocking 
toxins (e.g. α-Bungarotoxin) (Molenaar et al. 1991). In this model, Wistar rats are 
subcutaneously injected with α-bungarotoxin (α-BTX) every 48 h (QOD) for 3 weeks. α-BTX is 
well established as an irreversible antagonist of muscle nAChR containing α1 subunits. Several 
groups have presented evidences that the number of functional nAChRs in rat hemidiaphragms 
was significantly reduced after 2 - 3 weeks of α-BTX treatment, without evidencing a structural 
damage of muscle membranes (Plomp et al. 1992) and/or changes in the endplate AChE 
activity (Van Kempen et al. 1999). The Toxin-induced Myasthenia Gravis model (TIMG) 
(Molenaar et al. 1991) is used to better understand the underlying molecular mechanisms 
behind the NMT deficit. 
2.3. The neuromuscular junction 
The NMJ is a special type of synapse designed to efficiently transmit electrical impulses from 
myelinated motor nerves to the skeletal muscle cells. This synapse has three major structural 
elements: the motor neuron (or presynaptic region), the skeletal muscle fiber and the 
perisynaptic Schwann cell. The primary specializations include a terminal Schwann cell that 
caps the motor nerve, terminal branches of the motor axon, which accumulate mitochondria´s 
(provide energy for the synthesis and release of ACh, and microtubules) and synaptic vesicles 
(SVs), and an AChR-rich postsynaptic endplate (Hughes et al. 2006), where vesicles fuse with 
the membrane and release their contents into the synaptic cleft. In the presynaptic region there 
are also voltage-gated calcium channels (VGCC) of the P/Q- (presynaptic Cav2.1 voltage-gated 
calcium channels) and L-type (presynaptic CaV1 voltage-gated calcium channels) subtypes 
(Correia-de-Sá et al. 2000).  
The NMJ begins to form when the axon growth cone of developing motor neuron, or a sprouting 
motor axon, encounters a developing myotube, or a denervated muscle fiber, and begins to 
secrete a glycoprotein – agrin – with a laminin-binding domain that anchors it to the extracellular 
matrix, but requires the presence of postsynaptic transmembrane kinase, the muscle-specific 
kinase (MuSK). The agrin/MuSK interaction requires mutual binding to a third transmembrane 
muscle protein, the low density lipoprotein receptor-related protein 4 (LRP4). This process 
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induces dense clustering of the AChRs in the postsynaptic membrane and marked folding and 
specialization of that membrane (Hughes et al. 2006; Ha & Richman 2014). In the mature NMJ 
appear secondary specializations involving the formation of active zones along the junctional 
surface, distribution of the organelles asymmetrically, inside the nerve terminal, to the synaptic 
cleft, and the formation of secondary synaptic clefts, that creates folds in the postsynaptic 
membrane, where the nAChRs (ligand-gated ion channels) are clustered, while voltage-gated 
sodium channels (VGSC) concentrate in the depths of theses folds and also throughout the 
muscle membrane (Hughes et al. 2006). Stabilizers of the NMJ, such as proteins and 
proteoglycans, and the enzyme acetylcholinesterase (AChE) are also present in the synaptic 
cleft (Martyn et al. 2009) (Figure 1). 
 
Figure 1 - The mature NMJ and its main components: the nerve terminal (presynaptic region), the perisynaptic 
Schwann cell and the muscle fiber (specialized postsynaptic membrane). All 3 parts contain organelles and 
molecules not found in/or preferentially expressed when compared with extrasynaptic regions. (Martyn et al. 2009). 
Muscle nAChRs cooperate to facilitate fast NMT. Nicotinic receptors are pentameric 
transmembrane proteins, made up of combinations of 5 individual subunits (α, β, γ, δ and ε) that 
surround a central pore. In the adult NMJ, the stoichiometry of the muscle-type nAChRs is 
α2βδε. The binding of two molecules of ACh at the N-terminal domain of the interface between 
α/ε and α/β subunits induces a conformational change allowing the influx of sodium, thus 
leading to depolarization of the skeletal muscle membrane. Propagation of the action potential 
requires subsequent opening of voltage-sensitive sodium channel-rich valleys of the synaptic 
folds (Hughes et al. 2006; Ha & Richman 2014) (Figure 2-A). The rat NMJ is equipped with 
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α3β2 neuronal nAChR, which mediate the facilitation of ACh release, in addition to muscle-type 
nAChR containing the α1 subunit (Faria et al. 2003). 
After the initiation of an action potential, voltage-sensitive calcium channels open and the rapid 
increase in free Ca2+ in the nerve terminal initiates the mobilization and docking of SVs near 
active zones (fusion with the presynaptic membrane), which involve phosphorylation of 
synapsin and the formation of the soluble N-ethylmaleimide sensitive factor attachment receptor 
(SNARE) complex and, subsequent, release of ACh into the synaptic clefts (Hughes et al. 2006) 
(Figure 2-B). 
 
Figure 2 – The mature NMJ: A – VGSC= voltage-gated sodium channel, VGKC= voltage-gated potassium channel, 
VGCC= voltage-gated calcium channel; B – Schematic of MuSK and associated molecules responsible for nAChR 
clustering. (Ha & Richman 2014) 
The released ACh activates the nicotinc receptors (nAChRs) and the transmitter is rapidly 
hydrolyzed to acetic acid and choline by AChE in order to prevent continuous stimulation of 
nAChRs, preventing receptor desensitization, and allowing a higher safety margin of NMT. The 
choline is transported back into the nerve terminal, via sodium-dependent high-affinity choline 
transporters, and is re-used to synthesize new molecules of ACh by its combination with acetyl 
coenzyme A (Acetyl CoA), a reaction that is catalyzed by choline acetyltransferase (ChAT), 
which is produced in the cholinergic cell body and transported down the axon to the nerve 
endings (Hughes et al. 2006). 
Diseases of NMJ produce weakness which generally varies with repeated synaptic firing, 
sustained muscle contraction or repeated muscle contraction. The “true” myasthenias are 
characterized by weakness, which worsens with sustained muscle contraction or work and 
improves with rest. It has been determined that they primarily involve components of the 
postsynaptic portion of the NMJ and can be confirmed electrophysiologically by decrementing 
CMAPs, in response to slow rates of motor nerve stimulation (2-3 Hertz (Hz)), in association 
with normal amplitudes of the responses in case of a single nerve stimuli (Ha & Richman 2014).   
B A 
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2.4. Adenosine receptors in healthy and myasthenic motor endplates 
Adenosine (ADO) is a nucleoside involved in processes of the primary metabolism, such as the 
modulation of cellular metabolic state, and plays a modulatory role in the NMT, as it can be 
released from activated nerve terminals, from Schwann cells and from activated muscle fibers 
(Cunha 2005). ADO at the NMJ can be obtained by the catabolism of adenine nucleotides, 
when it is co-released with ACh from motor nerve terminals (Correia-de-Sá & Ribeiro 1996). 
The rate limiting step for ADO production from the hydrolysis of adenosine 5’-triphosphate 
(ATP) is dephosphorylation of adenosine 5’-monophosphate (AMP) by the ecto-5’-nucleotidase 
(CD73) (Cunha et al. 1996). Another source of extracellular ADO is cyclic adenosine 5’-
monophosphate (cAMP), which can be released from various cells including neurons, converted 
into AMP by extracellular phosphodiesterases, and thereafter into ADO by ecto-5´-nucleotidase 
(CD73) (Fredholm et al. 2001). Magalhães-Cardoso and collaborators (2003) showed that there 
is a shunt in the ADO formation at the rat NMJ, with the conversion of AMP into inosine 
monophosphate (IMP) by the enzyme ecto-AMP deaminase. Then, IMP is hydrolyzed into 
inosine (INO) by CD73, without ADO formation or the intervention of adenosine deaminase 
(ADA).  
Extracellular ADO initiates transmembrane signaling via four G protein-coupled receptors 
subtypes, bound to the plasma membrane, A1, A2A, A2B and A3. These receptors are structurally 
distinct and are encoded by four different genes. They are differentiated based on their coupling 
to cAMP production via the adenylate cyclase system. Cyclic AMP levels are dependent on the 
type of G protein coupled to the receptor: A1 and A3 receptors are coupled to Gi protein 
inhibiting adenylate cyclase, which leads to an intracellular decrease of cAMP levels. A2A and 
A2B receptors, are coupled to Gs protein, stimulate adenylate cyclase, which leads to an 
increase of cellular cAMP levels (Fredholm et al. 2001). ADO action depends on the receptor 
density, affinity and location, and in general the agonist is more efficient, when higher densities 
of the receptors are present. Therefore, low endogenous ADO levels, the ones observed under 
basal conditions, have the potential to activate the receptors only when they are in higher 
numbers, and not when these receptors are sparse (Fredholm et al. 2001). At the rat NMJ, high-
affinity A1 and A2A receptors are responsible for the major effects exerted by the ADO, namely at 
modulating synaptic transmission. Co-existence of both inhibitory A1R and facilitatory A2AR on 
the same nerve terminal was first proved using neurochemical and electrophysiological 
methods at the rat NMJ (Correia-de-Sá et al. 1991); later on it was shown that ADO could 
facilitate the release of neurotransmitter via activation of cAMP-coupled A2AR (Correia-de-Sá & 
Ribeiro 1994). The dual modulatory role of ADO via presynaptic inhibitory A1R and facilitatory 
A2AR is highly dependent on the nerve stimulation pattern (Correia-De-Sá et al. 1996), 
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particularly when this nucleoside is build-up from the catabolism of ATP release (Magalhães-
Cardoso et al. 2003). The tonic inhibitory effect mediated by A1R, is observed at low frequency 
stimulation under resting conditions, where low amounts of ADO activate predominantly 
inhibitory A1R. High-frequency, high-intensity motor nerve stimulation potentiates the tonic 
adenosine A2AR-mediated facilitation of ACh release, due to accumulation of ADO in the 
synaptic cleft, which may overcome muscular tetanic fade, whereas activation of the inhibitory 
A1R becomes less effective (Correia-de-Sá et al. 1996). During 50 Hz-trains, ATP is able to 
reach high levels, enough to inhibit CD73. Interburst intervals, allows the recovery from CD73 
enzymatic inhibition, because there is a delayed burst-like formation of ADO, leading to high 
synaptic concentrations of ADO, similar to those required to promote the activation of A2AR 
(Correia-de-Sá et al. 1996). 
A2AR act via subtle modifications of the presynaptic inter-receptor dynamics (Sebastião & 
Ribeiro 2000) involving the generation of intracellular second messengers, such as cAMP 
(Correia-de-Sá & Ribeiro 1994) and Ca2+ (Correia-de-Sá et al. 2000). It worth noting that fine-
tuning control of facilitatory nAChRs containing α3β2 subunits (Faria et al. 2003) and muscarinic 
M1 and M2 (Oliveira et al. 2002) receptors, is mediated by endogenous ADO. In parallel, there is 
a co-ordinate shift in Ca2+ cell dynamics operating ACh exocytosis, from the prevalent P/Q-type 
to the “facilitatory” L-type channel, in a way completely reversed by blocking A2AR activation 
(Oliveira et al. 2004). These mechanisms represent a novel form of synaptic plasticity mediated 
by ADO and may function to overcome neuromuscular tetanic depression during neuronal firing. 
Neurotransmission failure in MG is particularly evident during intense motor nerve activity, a 
situation where ADO, acting via A2AR, has a key role by promoting increases in the safety 
margin of NMT (Correia-de-Sá & Ribeiro 1996). 
Recently, our group demonstrated that A2AR fine-tuning control of NMT is impaired in animals 
models of MG (Noronha-Matos et al. 2011; Oliveira et al. 2015b). This seems to be mainly due 
to a decrease in endogenous ADO levels, leading to a reduction on tonic A2AR activity, which 
can be functionally recovered by application of the ADO precursor, AMP (Noronha-Matos et al. 
2011; Oliveira et al. 2015b). These findings led us to propose that changes in A2AR signaling 
dynamics might be associated to the pathogenesis of MG, therefore exploring new mechanisms 
to recover endogenous ADO amounts could be of clinical interest. 
3. Aim 
Nowadays, therapeutic strategies to control MG are mainly devoted to counteract immune 
response hyperactivity. To this end, corticosteroids are considered first line medications. 
Recently, our group demonstrated that methylprednisolone (MP 300 µM) increases ATP release 
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above baseline from resting motor endplates, which anticipates ADO accumulation at the 
synaptic cleft, thus contributing to amplify NMT via the activation of presynaptic facilitatory A2AR 
in healthy animals (Oliveira et al. 2015a). Sustained transmitter release due to facilitatory A2AR 
activation has been previously shown as an important mechanism to overcome tetanic 
depression in healthy individuals (Oliveira et al. 2004). Considering the data obtained in MG 
animal models, demonstrating that endogenous ADO generated in myasthenic motor endplates, 
during repetitive nerve stimulation is insufficient to sustain transmitter release demand through 
tonic activation of presynaptic facilitatory A2AR (Noronha-Matos et al. 2011; Oliveira et al. 
2015a), we hypothesized that corticosteroid benefits (avoidance of neuromuscular failure) in 
patients with MG may result from a mechanism that rehabilitates endogenous ADO 
accumulation at the neuromuscular synapse to levels high enough to activate presynaptic 
facilitatory A2AR, leading to increases in ACh release and muscular strength. The role of MP in 
the control of NMT and ATP release was evaluated by conventional neurochemical techniques 
(see e.g. Correia-de-Sá et al. 1991) and the ATP outflow was quantified by the luciferin – 
luciferase ATP bioluminescence (Oliveira et al. 2015a). 
4. Materials and methods 
4.1. Induction and clinical assessment of Experimental Autoimmune Myasthenia gravis 
(EAMG) rat models 
Females rats (Wistar Han) (Charles River, Barcelona, Spain), were kept at a constant 
temperature (21ºC) and a regular light (07.00–19.00 h) – dark (19.00 – 07.00 h) cycle, with food 
and water ad libitum. These animals were handled as stated in the Portuguese Decree - Law nº 
113/2013 of 7th August, concerning the protection of animals, used for experimental procedures 
and for other scientific purposes (Hau & Schapiro 2011). Their handling and experiments, were 
also in accordance with the guidelines prepared by the Committee on Care and Use of 
Laboratory Animal Resources (National Research Council, USA) and followed the European 
Communities Council Directive (86/609/EEC). These animals were randomly divided into three 
groups: Naïve, Control and Myasthenic (EAMG) groups. These animals were induced, and 
maintained in the vivarium according to the rules of Biotério ICBAS – UP. 
Under general anesthesia with the anesthetic medetomidine (0.5 mg/kg intraperitoneal (ip) 
/ketamine (75 - 90 mg/kg ip) combination (Rosenthal et al. 2008; Turner 2011; Papich 2011; 
Carpenter & Marion 2013), the rats in the EAMG group, were immunized by subcutaneous 
injection at six sites (two plantar regions, shoulders and bilaterally in the lower back) with 50 
microgram (µg) of R97-116 peptide (DGDFAIVKFTKVLLDYTGHI, JPT Peptide Technologies 
GmbH) – a synthetic peptide, corresponding to the region 97-116 of the rat nicotinic AChR α 
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subunit – emulsified in 200 microliters (µL) Complete Freund’s Adjuvant (CFA) (Sigma, St. 
Louis, MO, USA). Injections were performed on day 0 and were boosted on day 30 with the 
same peptide in Incomplete Freund’s adjuvant (Incomplete Freund’s Adjuvant (IFA) - lacks of 
Mycobacterium tuberculosis - 200 µL) (Baggi et al. 2004; Oliveira et al. 2015b). The Control 
group was immunized with CFA and IFA emulsions, respectively, containing phosphate-
buffered saline (PBS) instead of the nAChR R97-116 peptide at the respective time points. 
Animals in the Naïve group were left untreated.  
Each animal was weighed and evaluated for disease manifestation twice weekly until 
euthanized by decapitation on day 42 post immunization (pi) (Baggi et al. 2004; Oliveira et al. 
2015b). On the evaluation days, all the animals included in this study, were submitted to the 
same experimental procedure, and were examined equally. Evaluation of disease 
manifestations in immunized rats was performed by testing muscular weakness. Clinical scoring 
was based on the presence of tremor and hunched posture and muscle strength by grip 
strength test (BIOSEB, France), and fatigability was assessed after exercise (repetitive paw 
grips on the cage grid). Disease severity was graded using the follow clinical scoring: grade 0, 
normal strength and no muscle weakness; grade 1, normal at rest, but weak after exercise (chin 
on the floor; inability to raise head; hunched back); grade 2, clinical signs at rest; grade 3, 
severe clinical signs at rest, moribund, dehydrated and quadriplegic; and grade 4, dead (Baggi 
et al. 2004). The animals were also evaluated for loss of body weight, and for animal welfare 
critical points (Meredith & Redrobe 2002; Quesenberry & Carpenter 2012).  
The expression “Humane endpoints” becomes extremely important, and since “there are ethical, 
scientific and legal reasons for ensuring that adverse effects are minimized”, the “choice of 
appropriate humane endpoints provides significant opportunities for refinement, and should be 
developed in tandem with the requirements for a valid scientific outcome. Early endpoints 
reduce non-specific systemic effects and so may increase the precision of the results obtained.” 
(Workman et al. 2010) A new table of “Humane endpoints” was created based on the most 
common signals observed in the EAMG animals induced in the new vivarium. Was also 
adjusted to the alterations in the respiratory system observed, post grip strength test, and the 
induced behavior after manipulation of the animals (Attachment 2). A proper knowledge of the 
biology of these animals (Rattus norvegicus) is mandatory, to recognize signals of stress, pain, 
or any other unexpected behavior, and therefore has been taken into account in the 
development of the new table (Meredith & Redrobe 2002; Quesenberry & Carpenter 2012; Hau 
& Schapiro 2011). These “Humane endpoints” are in accordance with Portuguese Decree - Law 
nº 113/2013 of 7th August (Hau & Schapiro 2011), the guidelines prepared by the National 
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Research Council, USA, the guidelines of the Canadian Council On Animal Care (Olfert et 
al.1998), and the European Communities Council Directive (86/609/EEC).  
The animals were monitored for body weight, and for animal welfare critical points twice a week, 
except for the first 3 to 5 days, after the first and second boost which were monitored on a daily 
basis. A decreased or maintenance of body weight in the day 1 after the induction and also in 
the next day of the second boost (day 31), was observed in both the Control and EAMG groups. 
This was only due to decreased food intake during this period. Nevertheless, in Figure 3 which 
illustrates the weight variation over time, shows no significant differences, in the growth curves 
from the three groups of animals (Naïve n=3; Control n=27; EAMG n=29), which indicate that 
the muscle weakness, commonly observed in EAMG, did not interfere with the normal food 
intake. Between days 10 – 20 pi, all groups experienced weight loss, which we do not have a 
reasonable explanation for. 
 
Figure 3 – The weight variation over time (days pi) shows no significant differences, in the growth curves from the 
three groups of animals (Naïve ● n=3; Control □ n=27; EAMG▲ n=29). All the results are presented as mean +/- 
Mean standard error (SEM) .The vertical bars represent ± SEM. 
The onset and progression of the disease is expressed in terms of mean +/- SEM of the welfare 
score, and is illustrated in Figure 4 according with the new table of “Humane endpoints”, where 
the welfare of the animals was graded as follows: 0 – 4: Normal; 5 – 13: kept close attention 
and increase the frequency of motorization; 14 or more: pain, required veterinarian observation 
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and supportive care. Rats immunized with R97 – 116 peptide, presented a higher score (Figure 
4), with a medium value of 3.9 between days 0 – 30 pi, and 4.1 after day 30 pi (Table 1), and it 
is also observed that the Control group, with an average of 2.8 between days 0 – 30 pi, and 3.2 
after day 30 pi (Table 1), has levels of score, significant higher than the Naïve group (which 
have an average of 0,58 between days 0 – 30 pi, and 1.1 after day 30 pi) (Naïve n=3; Control 
n=27; EAMG n=29) (Table 1). 
 
Figure 4 – Clinical score of the three groups over time (days pi) - shows differences, between the groups of animals 
(Naïve ● n=3; Control □ n=27; EAMG▲ n=29). All the results are presented as mean +/- SEM (the vertical bars 
represent ± SEM). 
In Table 1 are presented the media values of the welfare score of these animals. 
 Day 0 – 30 pi After day 30 pi 
Naïve 0,58 1,1 
CFA 2,8 3,2 
EAMG 3,9 4,1 
 
Table 1 – Welfare average values of the clinical score obtained in the period between day 0 – 30 pi and after day 30 
pi. All animals were, in general, in the category - Normal (Naïve n=3; Control n=27; EAMG n=29). 
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The slight decreased or maintenance of the body weight previously referred, in both Control and 
EAMG groups, is coincident to the increase in the welfare score of these animals. These 
changes are a result of the sc inoculations inherent to the inducing protocol of EAMG, and the 
development and progression of the disease, that causes some discomfort. Despite that, the 
welfare average of the three groups is well below the alarming categories of the new table of 
“Humane endpoints” and the majority of the animals along the protocol demonstrated a normal 
behavior and welfare. 
4.2 Preparation and experimental conditions  
All animals were euthanized by decapitation, using a guillotine, a fast method, which has the 
advantage of allowing a good exsanguination; this may be required to enable the collection of 
blood samples for subsequent procedures. Then, the animals were submitted to surgical 
isolation of the phrenic nerve hemidiaphragm as described by Correia-de-Sá and Collaborators 
(1991) (Figure 5). 
 
Figure 5 – Surgical isolation of the phrenic nerve hemidiaphragm as described by Correia-de-Sá and Collaborators 
(1991), adapted from Oliveira 2013: A - Incision in the thoracic region; B - Removal of the ribs; C - Removal of 
parietal pleura; D - Isolation of phrenic nerve hemidiaphragm and dissection of the innerved diaphragm. 
The experiments were performed using either left or right phrenic nerve-hemidiaphragm 
preparations (4 - 6 millimeters (mm) width). Each muscle was superfused (5 mL.min−1, 37°C, pH 
7.4) with gassed (95% O2; 5% CO2) Tyrode´s solution (pH 7.4) containing (mM): NaCl 137, KCl 
2.7, CaCl2 1.8, MgCl2 1, NaH2PO4 0.4, NaHCO3 11.9 and glucose 11.2, at 37ºC (Correia-de-Sá 
et al. 1991). 
4.3. [3H]-ACh release experiment from phrenic nerve hemidiaphragm preparations 
The procedures used for labeling the preparations and measuring evoked [3H]-acetylcholine 
([3H]-ACh) release, have been previously described (Correia-de-Sá et al. 1991). Briefly, phrenic 
nerve-hemidiaphragm preparations were mounted in 3-mL capacity Perspex chambers heated 
to 37ºC. After a 30 min equilibration period, the perfusion was stopped and the nerve terminals 
A B C D 
17 
 
were labeled for 40 min with 1µM [3H]-choline (specific activity 2.5 µCi/nmol) under electrical 
stimulation, at a frequency of 1 Hz (0.04ms duration, 8mA). The phrenic nerve was stimulated 
with a glass–platinum suction electrode, placed near the first division branch of the nerve trunk, 
to avoid direct contact with muscle fibres (Figure 6). 
 
Figure 6 – Photography of the isolated phrenic nerve-hemidiaphragm preparations mounted horizontally in 
thermostatized organ bathes used to quantify the release of [
3
H]-ACh release experiment - isolated phrenic nerve 
hemidiaphragms preparations. Each phrenic nerve was inserted inside a suction electrode manufactured in the 
laboratory. 
After the labeling period, the preparations were again superfused (37.5 mL/min) and the nerve 
stimulation ceased. From this point onwards, hemicholinium-3 (10 µM) was present to prevent 
the uptake of [3H]-choline and the synthesis of unlabeled ACh. After a 60 min washout period 
1.5 mL, bath samples were automatically collected every 3 min using a fraction collector 
(Gilson, FC 203B, France) coupled with a peristaltic pump (Gilson, Minipuls3, France) 
programmed device by emptying and refilling the organ bath with the solution in use. The 
release of [3H]-ACh was evoked by two periods of electrical stimulation of the phrenic nerve, 
starting at min 12 (S1) and min 39 (S2), after the end of washout (zero time). Supramaximal 
intensity rectangular pulses (0.04 ms duration, 8 mA) were delivered at 50 Hz frequency. A 
series of 5 bursts of 150 pulses were applied, with a 20 s interburst interval - tetanic stimulation 
(Correia-de-Sá et al. 1996). Test drugs were added 15 min before S2 and were present up to 
the end of the experiments. Medium incubation aliquots (0.4 mL) were added to 3.5 mL of 
Packard Insta Gel II (USA) scintillation cocktail so that tritium content samples could be 
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measured by liquid scintillation spectrometry (counting efficiency of 40±2%). Radioactivity is 
expressed as DPM (disintegrations per minute). The evoked release of [3H]-ACh was calculated 
by subtracting the basal tritium outflow from the total tritium outflow during the stimulation period 
(Correia-de-Sá et al. 1996). The change in the ratio between the evoked [3H]-ACh released 
during the two stimulation periods (S2/S1), relative to the observed in control situations (in the 
absence of test drugs) was taken as a measure of drugs effects. 
4.4. Release of basal ATP from phrenic nerve hemidiaphragm preparations 
For ATP release experiments, the innervated hemidiaphragm preparations were mounted as 
described previously for radiochemical experiments. After a 30 min equilibration period, the 
perfusion was stopped and aliquots of 1.5 mL bath samples collected automatically every 3 min. 
During the first 6 min, the preparations were incubated with Tyrode´s solution; then MP 300 µM 
was added to the Tyrode’s solution for the next 24 min. Every 3 min samples were collected and 
the chambers refilled with fresh solution. Two hundred microliter aliquots were introduced into 
pre-cooled microtubes, which were frozen in liquid nitrogen until analysis The ATP content of 
the samples was evaluated by the luciferin – luciferase ATP bioluminescence assay kit HS II 
(Roche Applied Science, Indianapolis, Indiana). Luminescence was determined using a multi 
detection microplate reader (Synergy HT, BioTek Instruments) (Oliveira et al. 2015a). 
4.5. Drugs and Solutions  
Methylprednisolone sodium succinate (Solumedrol TM, Pfizer); choline chloride; hemicholinium-
3; CFA and IFA were obtained from Sigma, St. Louis, MO, USA; 4-(2-[7-Amino-2-(2-
furyl)[1,2,4]triazolo[2,3-a][1,3,5]t (ZM 241385) (Tocris Bioscience, Bristol, UK), made up in 
dimethylsulphoxide; [methyl-3H]choline chloride (ethanol solution, 80.6 Ci mmol-1) and the 
scintillation cocktail (Insta – gel Plus) were obtained from Perkin Elmer (Boston, USA); R97-116 
peptide (DGDFAIVKFTKVLLDYTGHI) was obtained from JPT Peptide Technologies GmbH. All 
stock solutions were stored as frozen aliquots at - 20ºC. Dilutions of these stock solutions were 
made daily. 
5. Results and Discussion 
5.1. Methylprednisolone-induced facilitation of transmitter exocytosis depends on tonic 
activation of A2AR on motor nerve terminals of EAMG rats  
Methylprednisolone (MP) is a glucocorticoid used in some neurological cases, both in human 
and veterinary medicine (Dickinson 2012).  
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Despite corticosteroids have been used for decades in the treatment of autoimmune myasthenic 
syndromes, the mechanism underlying the improvement of NMT is still a matter of debate. 
Recently, our group demonstrated that in healthy (Naïve) motor endplates, tetanic depression 
could be overcome by MP-induced facilitation of transmitter release (Oliveira et al. 2015a). Such 
a mechanism would be clinically relevant to explain corticosteroid benefits (avoidance of 
neuromuscular tetanic failure) in patients with Myasthenia Gravis. In this context, we decided to 
evaluate the effects of MP (300 µM) on evoked [3H]-ACh release during 50 Hz stimulation bursts 
of phrenic nerve hemidiaphragm preparation obtained from EAMG animals. 
 
Figure 7 – Facilitation of nerve-evoked [
3
H]-ACh release by methylprednisolone (MP) (300 µM), is mediated by tonic 
activation of A2AR on motor nerve terminals. Transmitter release was elicited by stimulation with 50 Hz Bursts of the 
phrenic nerve trunk (5 trains of 150 pulses applied with a 20 seconds interburst interval). Experiments were 
performed 6 weeks after immunization with the peptide R97-116 corresponding to the 𝛼-subunit of nAChR in CFA 
(EAMG), as compared to age-matched Naïve and Control littermates. A - MP was applied 15 min before the second 
period of stimulation (S2). The ordinates represent percentage of increase in the S2/S1 ratio, caused by MP (300 µM) 
application. B - MP was applied 15 min before the second period of stimulation (S2) either in the absence or presence 
of the selective A2AR antagonist, ZM 241385 (50 nM), which was present in S1 and S2. The ordinates represent the 
percentage of increase in the S2/S1 ratio, caused by MP (300 µM) application.  The vertical bars represent mean ± 
SEM p* < 0.05 (Mann-Whitney test) when comparing the effect of MP in the presence and absence of ZM 241385.  
Incubation of hemidiaphragm preparations from Control and EAMG rats with MP (300 µM) 15 
min before S2 increased significantly (p<0.05) [
3H]-ACh release triggered by phrenic nerve 
stimulation with 50 Hz bursts (150 pulses applied 5 times with a 20 s interburst interval) (Figure 
7-A). No significant changes (p˃0.05) were detected when comparing the facilitatory effect of 
MP (300 µM) in EAMG rats (33±1%, n=5) with Controls (24±3%, n=6) and Naïve (40±11%, n=5) 
animals. Since the methylprednisolone-induced tetanic enhancement of NMT in Naïve animals 
depends on tonic activation of presynaptic facilitatory A2AR (Oliveira et al. 2015a) we designed 
experiments to test if these receptors are also involved in corticosteroid induced amplification of 
NMT in myasthenic animals. Experiments were designed to evaluate the effect of MP (300 µM) 
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on evoked [3H]-ACh release induced by 50 Hz bursts in the presence of the selective A2AR 
antagonist, ZM241385 (50 nM). As observed in Naïve rats, amplification of transmitter release 
by the MP (300 µM) depend on tonic A2AR activation because pre-treatment of hemidiaphragm 
preparations with ZM241385 (50 nM) prevented the facilitatory effect of MP (300 µM) in both 
control (-9±11%, n=3) and EAMG (-16±19%, n=3) animals (Figure 7-B). 
In observational studies, remission or marked improvement is seen in 70–80% of patients with 
MG, treated with oral corticosteroids indicating that therapeutic approaches using 
corticosteroids are highly effective (Sathasivam 2008). Until now the clinical benefits of 
corticosteroids in MG are mainly attributed to their immunosuppressive effects. Steroids are 
thought to inhibit the activation of T cells by interfering with the activation process in the cell 
nucleus (Allison 2000). In addition, steroids impair the function of cells of the monocyte–
macrophage lineage by inhibiting antigen processing and decreasing the number of circulating 
T cells (Taylor et al. 2005). In this work, we show for the first time that in addition to their 
immunosuppressive action corticosteroids can improve the clinical features of MG. The 
corticosteroid, MP, can rehabilitate NMT failure in EAMG animals by amplifying neurotransmitter 
release.  
Typically, MG patients present with a history of weakness and fatigability of muscles on 
sustained or repeated activity which corresponds to nerve stimulation increases from 5 to 50 Hz 
(Conti-Fine et al. 2006; Hirsch 2007). In this context our results gain pathophysiological interest 
since the beneficial effects of corticosteroids operates only at nerve stimulation frequencies of 
50 Hz-Bursts (Oliveira et al 2015a). At high frequency (50 Hz) stimulation, a coordinated shift 
from a prevailing A1-inibitory towards A2A-facilitatory tonus on NMT modulation occurs at healthy 
motor nerve endplates (Correia-de-Sá et al. 1996). This constitutes an important mechanism to 
sustain transmitter release and to overcome tetanic depression in healthy conditions (Oliveira et 
al. 2004). However, in myasthenic motor nerve endplates the sustained transmitter release 
mediated by tonic A2AR activation is impaired (Oliveira et al. 2015b). Interestingly, in this work 
we demonstrated that the corticosteroid also exerts its beneficial effect on myasthenic animals 
by recruiting the presynaptic facilitatory A2AR.  
Moreover, we showed that in healthy animals amplification of NMT by MP involves a 
predominant activation of presynaptic facilitatory A2AR, leading to synaptic vesicles redistribution 
favoring transmitter exocytosis during high-frequency neuronal firing. Whether this mechanism 
underlying endo/exocytosis modifications operates in EAMG motor nerve terminals requires 
further investigations. 
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Due to their immunosuppressive and neuromodulatory actions pharmacological targeting of 
A2AR activity constitutes an appealing therapeutic strategy for MG patients (Oliveira et al. 
2015a).  We have recently demonstrated that insufficient amounts of ADO to promote immune 
cells immunosuppression and NMT via A2AR activation occur in EAMG animals (Oliveira et al. 
2015b). In Naïve rats tonic activation of facilitatory A2AR by endogenous ADO generated from 
ATP released, under resting conditions, is vital for methylprednisolone-induced facilitation of 
transmitter release during high-frequency bursts (Oliveira et al. 2015a). In fact, increments of 
extracellular ATP derived ADO formation favoring A2AR activation may be crucial to rehabilitate 
cell communication deficits in myasthenics, since immune suppression and NMT deficits in 
EAMG animals may be rehabilitated by A2AR activation by exogenous AMP application  serving 
as an ADO precursor (Oliveira et al. 2015b).  
In this context we decided to investigate the time course of MP (300 µM) induced ATP release 
in non-stimulated phrenic nerve hemidiaphragm preparations collected from all animal groups, 
using the luciferin-luciferase bioluminescence assay. 
 
Figure 8 - Increase in the resting ATP outflow at the rat neuromuscular junction, induced by methylprednisolone (300 
µM). A – Time-course of basal ATP outflow from innervated hemidiaphragm preparations in the presence or absence 
of MP (300 µM) collected from rats immunized with the peptide R97-116 corresponding to the 𝛼-subunit of nAChR in 
CFA (EAMG), and to age-matched Naïve and Control littermates. Abscissa indicates the times at which samples 
were collected. B – Average mean value of basal ATP outflow in the presence and absence of MP (300 µM) for all 
animal groups. p* < 0.05 (Mann-Whitney test) when comparing the basal ATP release induced by MP (300 µM) 
application with basal ATP release in the control conditions. 
In all animal groups, application of MP (300 µM) rapidly increase basal ATP outflow from 
phrenic nerve-hemidiaphragm preparations (Figure 8-A). The maximum peak in basal ATP 
release was observed 3 min after MP (300 µM) application in Naïve (991±170 pM) and EAMG 
animals (1093±175 pM) (Figure 8-A). Interestingly, the increase in ATP outflow was kept at high 
levels for the time of MP (300 µM) application (18 min) in all groups of animals (Figure 8-A). The 
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average basal ATP outflow during MP (300 µM, 18 min) application was always higher than 
baseline in Naïve (765±57 vs 481±33 pM n=3), Control (653±101 vs 401±82 pM n=6) and 
EAMG (794±71 vs 526±71 pM n=5) animals (Figure 8-B). 
Data show here that MP can rehabilitate NMT failure in EAMG animals by increasing the 
outflow of ATP from resting motor endplates, which upon its extracellular hydrolysis into ADO 
may increase the A2AR tonus, leading to facilitation of evoked transmitter release during high-
frequency nerve firing. 
ATP can be released to the extracellular compartment by non-lytic mechanisms including: (1) 
exocytosis of ATP-containing vesicles; 2) through nucleotide-permeable channels (connexin 
and pannexin hemichannels, maxi-anion channels, volume-regulated anion channels or P2X7 
receptor channels); (3) via transport vesicles that deliver proteins to the cell membrane; (4) via 
lysosomes. The contribution of these mechanisms on MP induced ATP outflow deserves further 
investigations. Taking into consideration that long-term use of corticosteroids is associated with 
many adverse events, including Cushingoid symptoms, infections, hypertension, diabetes, 
osteoporosis, psychiatric disorders, insomnia, and elevations in white blood cell count, the need 
of achieving new pharmacological target with the same efficiency and with less side effects 
emerges. As stated previously pharmacological targeting of A2AR activity in MG constitutes an 
appealing target. So, understanding the mechanisms associated to MP induced ATP release 
and A2AR activity may give important insights to unravel new pharmacological strategies for MG 
treatment. 
6. Conclusion 
Recent research has increases our understanding of NMT, which allowed the development of 
better diagnostic techniques to identify MG patients sooner, providing the establishment of 
supportive therapy in the earlier state of the disease. The conventional method of treatment with 
AChE inhibitors is still a viable treatment, but in severe cases early in the course of MG, may be 
required immunosuppressive drugs, which sometimes are insufficiently to control the symptoms 
during inflammatory crisis (Khorzad et al. 2011). It is clear that randomized controlled trials are 
necessary to determinate the most effective therapy.     
Neurotransmission failure in MG is particularly evident during intense motor nerve activity, a 
situation where ADO, acting via A2AR, has a key role by promoting increases in the safety 
margin of NMT (Correia-de-Sá & Ribeiro 1996). Our group provided evidence showing that tonic 
activation of presynaptic facilitatory A2AR may contribute to overcome tetanic depression during 
high-frequency neuronal firing in healthy rats (Oliveira et al. 2004), we strongly believe that 
presynaptic manipulation of A2AR activity might prove therapeutically useful for myasthenic 
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syndromes. In fact, a dysfunction on A2AR activity seems to contribute to the pathophysiology of 
myasthenic syndromes, since during nerve stimulation endogenous ADO generated in 
myasthenic motor endplates is insufficient to sustain transmitter release demand through tonic 
activation of presynaptic facilitatory A2AR (Noronha-Matos et al. 2011; Oliveira et al. 2015a). In 
this work we demonstrated that corticosteroid commoly used in the treatment of MG increases 
ATP release above baseline from resting myasthenic motor endplates, which anticipates ADO 
accumulation at the synaptic cleft, thus contributing to amplify NMT via the activation of 
presynaptic facilitatory A2AR, leading to transmitter exocytosis during high-frequency neuronal 
firing. These findings contribute to elucidate the non-immunological beneficial effects of 
corticosteroids in NMT deficits, and confirm that ADO path may be a key target for therapeutic 
intervention in MG (Oliveira et al. 2015b). 
The mechanism underlying non-genomic glucocorticoid-induced ATP release from innervated 
skeletal muscles deserves further elucidation.  
Further insights on some of these issues would allow a better understanding of the biochemical 
and molecular mechanisms involved in the pathophysiology of ADO signaling pathways in 
myasthenic disorders and, perhaps, would unravel new avenues towards novel therapeutic 
approaches for myasthenic syndromes. 
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8. Attachments 
Attachment 1 - Similarities and differences between MG and EAMG. Adapted from Baggi et al. 
2012. 
 Similarities Differences 
 
Immunopathological features 
 
Presence of anti-AChR Abs in the 
serum; 
 
Deposits of IgGs and C3 
complement component at the NMJ; 
 
Loss of muscle nAChRs; 
 
MHC class II-restricted presentation 
of AChR epitopes; 
 
Involvement of T helper cells in B -
cell antibody production. 
 
Disease does not arise 
spontaneously in animals,  needs  
for induction factors; 
 
Involvement of the thymus (present 
in some cases of MG, absent in 
EAMG). Thymic alterations are 
absent in EAMG, and    in MG 
patients, hypertrophy and thymomas 
are often present; 
 
Phagocytic cells detected in the 
acute phase of rat EAMG, are 
absent at the NMJ of human MG 
patients. 
 
Clinical manifestations 
 
Muscle weakness, most prominent 
in the upper body; 
 
Decreased response in the 
repetitive nerve stimulation test; 
 
Reduction in the miniature end-plate 
potential amplitude; 
 
Temporary improvement in muscle 
strength after anti-AChE treatment 
(Tensilon test). 
 
Absence of ocular signs; 
 
Absence of relapse and remission 
periods. 
 
MG patients and EAMG share several features, in particular muscle weakness, fatigability and 
decremented response after repetitive nerve stimulation. When treated with anti-cholinesterase drugs 
occurs a temporary improvement of strength, and appear similarities in many immunopathological 
features, such as presence of anti-AChR Abs in serum, deposition of IgGs at the NMJ, MHC II 
presentation of AchR epitopes and involvement of T helper cells in B cell Abs production (Baggi et al. 
2012). Also, in contrast with MG in humans, the disease is not spontaneously in animals (Baggi et al. 
2004). 
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Attachment 2 - Table to evaluate the "Humane Endpoints" of the “Projecto nº 174 – Miastenias” 
(Oliveira & Mota 2014) 
 
